ExThera Medical's CEO Bob Ward to Present at 'OneMedForum 2013' Next Week in San Francisco
ExThera Medical announced today that its President and CEO, Bob Ward, will present ExThera Medical's opportunity at ‘OneMedForum 2013.' Dr. Ward's presentation will be at The Sir Francis Drake Hotel beginning at 2:40 p.m. PST on Tuesday, Jan. 8th.
ExThera's Seraph™ (Selective Removal by Apheresis) Microbind™ Affinity Blood Filter has received enthusiastic scientific scrutiny for its potential to bind a wide range of pathogens, toxins and pro-inflammatory cytokines to thwart bacteremia and viremia in the prevention of sepsis.
While other medical treatments of bacteremia caused by S. aureus or MRSA (Methicillin-Resistant S. Aureus) rely on antibiotics with failure rates up to 40%, the Seraph™ apheresis device capitalizes on the affinity of the bacteria in an infected patient's blood to attach to immobilized heparin—a natural anticoagulant, with many other biological attributes. Seraph™ is designed to be a biomimetic adjunct to antibiotic therapy that reduces bacterial load and duration of bacteremia while lowering levels of pro-inflammatory cytokines in a patient's blood, thereby preventing complications such as endocarditis, osteomyelitis, and sepsis.
Although presently aimed at its prevention, another critically important application of Seraph™ is expected to be the treatment of sepsis within intensive care units (ICU). Seraph™ consists of a specially designed cartridge packed with a novel bioactive polymer substrate that acts as a hemofilter. By incorporating immobilized heparin, and supplemental ligands the cartridge's high-surface-area may safely and selectively reduce pro-inflammatory cytokines such as TNF-alpha and remove many toxins and pathogens such as S. aureus including MRSA, from a patient's blood before the blood is (re)infused.
About ExThera Medical
Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood-borne diseases including bacteremia and sepsis, as well as the removal of harmful substances present in banked human blood.
CAUTION: ExThera Medical's products are for investigational use only.
Ronald Trahan Associates Inc.
Ronald C. Trahan, APR, President, +1-508-359-4005, x108